The Journal of the American Medical association, recently published findings of a new cohort study aimed to examine the risk of pioglitazone and baldder cancer risk as well as additional cancer risks. The study focused on the usage, duration, cumulative dose and time of starting of pioglitazone therapy. Previously, pioglitazone studies suggested increased risk for bladder cancer. At the end of this observational analysis the researchers concluded that pioglitazone is not associated with a statistically significant increase risk of bladder cancer. The study also concluded that there was an increased risk for prostate and pancreatic cancer. However, more studies should be done to support findings. How often do you see pioglitazone prescribed and dispensed?
For more information please see JAMA
Image courtesy of [Stuart Miles]/FreeDigitalPhotos.net